Day: June 28, 2021

Date: Friday, August 6, 2021Time: 11:00 a.m. (Eastern Time) BROOKFIELD NEWS, June 28, 2021 (GLOBE NEWSWIRE) — You are invited to participate in Brookfield Business Partners’ 2021 Second Quarter Conference Call & Webcast on Friday, August 6, 2021 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. Results will be released on Friday, August 6, 2021 prior to 8:00 a.m. (Eastern Time) and will be available following the release on our website at https://bbu.brookfield.com. To participate in the Conference Call please dial +1 (866) 688-9431 toll-free in the U.S. and Canada or for overseas calls please dial +1 (409) 216-0818 (Conference ID 4867584) at approximately 10:50 a.m. (Eastern Time). Live audio of the Conference Call will be available via webcast on our website...

CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today commented on the recent decision by Health Canada to re-issue a Notice of Compliance (“NOC”) for Ruzurgi® (amifampridine tablets), once again allowing the product to be marketed in Canada for patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Health Canada’s original NOC for Ruzurgi® for marketing in Canada was quashed in a recent decision of the Federal Court of Canada, which sent the matter back to Health Canada to re-determine its decision to grant marketing authority to Ruzurgi® despite Firdapse’s®...

RADNOR, Pa., June 28, 2021 (GLOBE NEWSWIRE) —  Safeguard Scientifics, Inc. (NYSE:SFE) (“Safeguard” or the “Company”) today announced an update to the fair value of its ownership interest in Bright Health Group (“Bright Health”), a leading national high-growth integrated healthcare platform.   On June 23, 2021, Bright Health completed an initial public offering (“IPO”), which included the conversion of its preferred stock into shares of common stock in conjunction with a stock split.   With the completion of the IPO, Safeguard’s stake in Bright Health consists of approximately 1.3 million shares of common stock, subject to the final determination by Bright Health’s transfer agent. Based on the IPO closing price of $18.00 per share, Safeguard’s position in Bright Health is valued at approximately $23.4 million, as compared to $15.3...

Frontline Ltd. (NYSE and OSE: FRO) (“Frontline” or the “Company”) today announces that it has entered into an agreement to acquire two scrubber fitted, latest generation ECO-type VLCCs built in 2019 at Hyundai Heavy Industries (“HHI”) shipyard in South Korea for a total of $180.0 million. The vessels are scheduled to deliver during fourth quarter of 2021. Frontline intends to meet the financing of this acquisition with existing borrowing facilities and establish long term financing closer to delivery of the vessels. Lars H. Barstad, Interim CEO of Frontline Management AS said: “Frontline continues to execute on our strategy to position the Company towards what we believe will be a firm recovery as oil demand, and subsequently oil supply returns to pre pandemic levels. We have over the last periods seen the benefits of running a modern...

PHILADELPHIA, PA, June 28, 2021 (GLOBE NEWSWIRE) — FinTech Acquisition Corp. VI (NASDAQ:FTVIU) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced the completion of its initial public offering of 25,000,000 units at a price of $10.00 per unit, which includes 3,000,000 units issued pursuant to the exercise of the underwriters’ over-allotment option, for gross proceeds to the Company of $250,000,000. The Company’s units began trading on the Nasdaq Capital Market under the symbol “FTVIU” on June 24, 2021. Each unit issued in the offering consists of one share of the Company’s Class A common stock and one-fourth of one warrant, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share....

HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) — VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) (“VAALCO” or the “Company”) today announced that it has issued its 2020 Environmental, Social and Governance (“ESG”) report, which is now available on VAALCO’s web site, www.vaalco.com, under the “Sustainability” tab. This report provides detailed information about VAALCO’s ESG initiatives and related key performance indicators for the three-year period 2018 through 2020. In the creation of this document, the Company consulted the Sustainability Accounting Standards Board’s (“SASB”) Oil and Gas Exploration and Production Sustainability Accounting Standard, the recommendations of the Task Force on Climate-related Financial Disclosures (“TCFD”), the Sustainable Development Goals (“SDG’s”) promulgated by the United Nations and other reporting guidance...

WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock. Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Securities are acting as joint book-running managers for the proposed offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. A...

Submission supported by previously announced data from Phase 3 MPOWERED™ study NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of MYCAPSSA® (oral octreotide capsules) as a maintenance therapy for adults with acromegaly. The MAA is supported by positive results from Chiasma’s global Phase 3 MPOWERED™ non-inferiority clinical trial comparing MYCAPSSA to long-acting injectable somatostatin analogs...

SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. In addition, Aligos intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock. All of the shares of common stock are being offered by Aligos. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering. A registration statement relating to these securities has been filed with the Securities...

Company announcement – No. 42/ 2021 ZEALAND PHARMA A/S – SHARE BUY-BACK PROGRAM UNDER SAFE HARBOUR TO AQUIRE DANISH COMMON STOCK FOR EMPLOYEE INCENTIVE PROGRAMS On 29 June 2021, Zealand Pharma A/S (“Zealand”) will initiate a share repurchase program in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbor Regulation”).  Zealand has entered an arrangement with Danske Bank A/S to act as exclusive manager under the program. Danske Bank A/S will buy back shares on behalf of Zealand and make related trading decisions independently of and without influence by Zealand. The share repurchase program will be implemented under the following terms:The maximum total consideration for...